Study of Talimogene Laherparepvec Administered Endoscopically for the Treatment of Locally Advanced or Metastatic Pancreas Cancer Refractory to at Least One Chemotherapy Regimen
Latest Information Update: 17 Jul 2024
At a glance
- Drugs Talimogene laherparepvec (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 09 Jul 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 29 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 02 Aug 2022 Planned primary completion date changed from 1 Apr 2022 to 1 Dec 2022.